Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos

By /

Speaking to BioSpace at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss pharma hasn’t acquired a GLP-1, and why it probably won’t.

Scroll to Top